Menopause Hormone Therapy: New Guidelines, New Perspectives

Menopause Hormone Therapy: New Guidelines, New Perspectives

Menopause care is changing. New guidelines support hormone therapy for eligible women, but what do the latest recommendations say about treatment options, benefits, risks, and long-term use?

In This article

  • New menopause guidelines emphasize individualized decision-making and support hormone therapy as a first-line treatment for vasomotor symptoms and associated sleep disturbances in eligible women.

  • Hormone therapy is generally most favorable for women younger than 60 or within 10 years of menopause onset, although decisions about continued treatment should be individualized.

  • Nonhormonal treatments, including fezolinetant, elinzanetant, selected antidepressants, and gabapentin, offer alternatives for women who cannot or choose not to use hormone therapy.

  • Menopausal hormone therapy is not a first-line treatment for major depression or anxiety disorders, but research suggests estradiol may improve mood symptoms in some perimenopausal women.

  • Mental health providers can play an important role in recognizing menopause-related symptoms, providing evidence-based information, and helping women navigate treatment decisions and access knowledgeable menopause clinicians.

Menopause is finally having its moment. Over the last several years, there has been growing public awareness of the symptoms associated with the menopausal transition, increased attention to the impact of menopause on women’s health and quality of life, and renewed interest in treatment options, particularly menopausal hormone therapy. This shift has been accompanied by important changes in clinical recommendations, reflecting a more nuanced understanding of the benefits and risks of hormone therapy and a move toward individualized treatment.

In October 2026, major U.S. medical groups—including the American College of Obstetricians and Gynecologists (ACOG)—updated their clinical guidelines to strongly recommend hormone therapy (HT) as a first-line treatment for hot flashes, night sweats, and related sleep issues in eligible individuals. 

ACOG replaced its 2014 guidance with its most comprehensive menopause recommendations to date. While the 2014 recommendations provided rigid rules on the use of hormone therapy, recommending the lowest dose for the shortest time, the 2026 guidelines encourage shared, individualized decision-making. 

Key Updates on Menopause Hormone Therapy

  • First-line relief: Systemic hormone therapy is strongly recommended for vasomotor symptoms (hot flashes and night sweats) and associated sleep disturbances when no contraindications exist. 
  • Protection of the uterus: Estrogen plus a progestogen is recommended for those with a uterus to protect the uterine lining, while estrogen alone is recommended for those who have had a hysterectomy. 
  • Timing matters: Starting hormone therapy is generally advised before the age of 60 or within 10 years of menopause onset. Continuing past age 60 can still be considered individually to manage ongoing symptoms.
  • Contraindications: Hormone therapy is generally avoided in people with a history of breast cancer, blood clots, stroke, heart attack, active liver disease, unexplained vaginal bleeding, or pregnancy. 

Non-Hormonal Medications and Other Therapies

  • Targeted non-hormonal drugs: Neurokinin receptor antagonists—specifically fezolinetant and elinzanetant—are strongly recommended for hot flashes in people who cannot or choose not to take hormones. 
  • Antidepressants and other options: Certain SSRIs and SNRIs (such as paroxetine, escitalopram, venlafaxine, and desvenlafaxine) and gabapentin remain options for vasomotor symptoms, with SSRIs/SNRIs also used for mood symptoms.
  • Behavioral and lifestyle support: Cognitive behavioral therapy (CBT), mindfulness, exercise, clinical hypnosis, and acupuncture are conditionally supported alongside medical care for the management of vasomotor symptoms and sleep.
  • What isn’t recommended: Over-the-counter herbal supplements/phytoestrogens, DHEA, testosterone, and progestogen alone are not recommended for hot flashes, sleep, or mood. Evidence is also considered insufficient to recommend hormone therapy specifically for depression. 

(Note: ACOG plans to release separate guidance on genitourinary syndrome of menopause—such as vaginal dryness and urinary symptoms—in 2027.)

Menopause Hormone Therapy for Perimenopausal Mood and Anxiety Disorders

In our clinic, we have seen a marked increase in the number of perimenopausal and early postmenopausal women presenting with questions about hormone therapy. These patients typically present with a constellation of symptoms, including depression, irritability, sleep disturbance, cognitive difficulties, and fatigue. This shift likely reflects growing awareness of the burden associated with the menopausal transition and a major change in how menopausal hormone therapy is viewed in the medical community. 

A key clinical question for mental health providers is whether MHT should be considered as a treatment for depression and/or anxiety symptoms emerging in the menopausal transition. At present, MHT is not considered a first-line treatment for major depressive disorder or anxiety disorders in midlife women. However, a growing body of research suggests that estradiol may have antidepressant and anxiolytic effects in some perimenopausal women, especially when there is a clear temporal association between mood symptoms and hormonal fluctuations.

While MHT may not be considered as a first-line intervention for the treatment of perimenopausal mood and anxiety symptoms, MHT may be considered as a potential adjunctive or parallel intervention in specific clinical contexts, in collaboration with a clinician who prescribes menopause care.

Finding a Knowledgeable Provider

Despite accumulating data supporting the use of MHT in selected perimenopausal and postmenopausal women, most gynecologists and internists currently in practice trained after data from the Women’s Health Initiative strictly limited the use of hormone replacement therapy. Many clinicians report limited education in contemporary MHT prescribing, including choice of route, dose, and duration and strategies for evaluating benefit–risk in complex midlife patients.

As a result, perimenopausal women frequently struggle to find clinicians who feel comfortable discussing or prescribing hormone therapy, even when they have significant symptoms that impair quality of life. Into this gap, a number of virtual and direct-to-consumer menopause services have emerged, offering telehealth consultations and MHT prescribing outside traditional health-care systems. While these platforms may increase access, many women feel uneasy about receiving prescriptions from unfamiliar clinicians or online companies.

Mental health providers may be the first to hear about these symptoms. While most mental health providers do not prescribe MHT, we can play a crucial role in validating symptoms, providing current, balanced information about MHT, and supporting patients in shared decision-making with their gynecologist or primary care provider.

Read: A Primer on Menopausal Hormone Therapy for Mental Health Providers

The Menopause Society Certified Practitioner designation identifies clinicians who have passed a competency exam and complete ongoing education in midlife women’s health. The Menopause Society Practitioner Directory can be used to filter by ZIP code and select providers who provide care  in an office setting. 

—Ruta Nonacs, MD PhD

Share:

MOST RECENT

Keep Reading

Go to Top